John Gordon Foulkes
Chief Executive Officer at Lipidio Pharmaceuticals, Inc.
Profile
John Gordon Foulkes was the founder of Excaliard Pharmaceuticals, Inc. where he held the title of President & Director from 2010 to 2011.
He was also the founder of Kaperio, Inc., Thirona Bio, Inc. and Lipidio Pharmaceuticals, Inc. where he previously held the title of Chief Executive Officer & Director.
Dr. Foulkes received his undergraduate degree from Massachusetts Institute of Technology and his doctorate degree from the University Of Dundee in 1980.
John Gordon Foulkes active positions
Companies | Position | Start |
---|---|---|
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | Chief Executive Officer | - |
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | Founder | - |
Former positions of John Gordon Foulkes
Companies | Position | End |
---|---|---|
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri. | Private Equity Investor | 31/12/2010 |
Kaperio, Inc.
Kaperio, Inc. Medical/Nursing ServicesHealth Services Kaperio, Inc. operates as a biopharmaceutical company which focuses on cardiovascular disease. It develops site targeted drugs and molecular imaging agents for cancer and cardiovascular disease. The company was founded by J. Gordon Foulkes and is headquartered in St. Louis, MO. | Founder | - |
Redwood Bioscience, Inc.
Redwood Bioscience, Inc. BiotechnologyHealth Technology Redwood Bioscience Inc. develops precision protein-chemical engineering technology to produce the next-generation of antibody-drug conjugates and other semi-synthetic biotherapeutics. It employs natural post translational modifications found in human cells to site specifically create one or more aldehyde tags on protein molecules, including monoclonal antibodies. The firm's platform is enabled with precision chemistries, payload positioning and defined stoichiometry of payload protein ratios. The company was founded by Carolyn R. Bertozzi, Mike Blank and David Rabuka in 2008 and is headquartered in Emeryville, CA. | Chairman | - |
Thesan Pharmaceuticals, Inc.
Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA. | Chief Executive Officer | - |
Excaliard Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Founder | - |
Training of John Gordon Foulkes
Massachusetts Institute of Technology | Undergraduate Degree |
University Of Dundee | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 12 |
---|---|
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri. | Finance |
Cengent Therapeutics, Inc.
Cengent Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cengent Therapeutics, Inc. used to research and develop pharmaceutical drugs. It was a structure-based drug discovery company with a primary focus on compounds targeting signal transduction for the treatment of obesity and diabetes. It used to discover orally active PTP-1B inhibitors for treatment of type II diabetes and obesity. It was headquartered in San Diego, CA. | Commercial Services |
Oncogene Science, Inc.
Oncogene Science, Inc. Medical/Nursing ServicesHealth Services Oncogene Science, Inc. provided cancer diagnostics services. The company was founded in 1983 and was headquartered in Uniondale, NY. | Health Services |
Aurora Biosciences Corp.
Aurora Biosciences Corp. BiotechnologyHealth Technology Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA. | Health Technology |
Elitra Pharmaceuticals, Inc.
Elitra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Elitra Pharmaceuticals, Inc. used to develop pharmaceutical products. The company employed proprietary methods for gene analysis and anti-microbial drug discovery. It used to develop technology to miniaturize anti-microbial drug screens. It was also engaged in the identification, development and commercialization of novel antimicrobial compounds that target essential gene products of pathogenic organisms. The company was founded in 1997 and was headquartered in San Diego, CA | Health Technology |
Vitra Bioscience, Inc.
Vitra Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Vitra Bioscience, Inc. develops technologies for biological research and drug discovery. Its technology includes cellcard system and cellplex assays which facilitate multiple cell-types and parameters to be evaluated. The cellcard imaging system collects images and then analyzed with proprietary software. The company was founded by Simon Goldbard and is headquartered in Mountain View, CA. | Health Technology |
Excaliard Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Health Technology |
Thesan Pharmaceuticals, Inc.
Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA. | Health Technology |
Redwood Bioscience, Inc.
Redwood Bioscience, Inc. BiotechnologyHealth Technology Redwood Bioscience Inc. develops precision protein-chemical engineering technology to produce the next-generation of antibody-drug conjugates and other semi-synthetic biotherapeutics. It employs natural post translational modifications found in human cells to site specifically create one or more aldehyde tags on protein molecules, including monoclonal antibodies. The firm's platform is enabled with precision chemistries, payload positioning and defined stoichiometry of payload protein ratios. The company was founded by Carolyn R. Bertozzi, Mike Blank and David Rabuka in 2008 and is headquartered in Emeryville, CA. | Health Technology |
Kaperio, Inc.
Kaperio, Inc. Medical/Nursing ServicesHealth Services Kaperio, Inc. operates as a biopharmaceutical company which focuses on cardiovascular disease. It develops site targeted drugs and molecular imaging agents for cancer and cardiovascular disease. The company was founded by J. Gordon Foulkes and is headquartered in St. Louis, MO. | Health Services |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | Health Technology |
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- John Gordon Foulkes